Hls Therapeutics Stock Performance
| HLTRF Stock | USD 4.02 0.00 0.00% |
HLS Therapeutics has a performance score of 13 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.59, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning HLS Therapeutics are expected to decrease at a much lower rate. During the bear market, HLS Therapeutics is likely to outperform the market. HLS Therapeutics currently retains a risk of 0.76%. Please check out HLS Therapeutics jensen alpha and rate of daily change , to decide if HLS Therapeutics will be following its current trending patterns.
Risk-Adjusted Performance
Good
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in HLS Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. Despite nearly inconsistent basic indicators, HLS Therapeutics may actually be approaching a critical reversion point that can send shares even higher in December 2025. ...more
| Begin Period Cash Flow | 20.6 M | |
| Total Cashflows From Investing Activities | -4.5 M |
HLS |
HLS Therapeutics Relative Risk vs. Return Landscape
If you would invest 370.00 in HLS Therapeutics on August 2, 2025 and sell it today you would earn a total of 32.00 from holding HLS Therapeutics or generate 8.65% return on investment over 90 days. HLS Therapeutics is currently producing 0.1325% returns and takes up 0.7642% volatility of returns over 90 trading days. Put another way, 6% of traded pink sheets are less volatile than HLS, and 98% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
HLS Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for HLS Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as HLS Therapeutics, and traders can use it to determine the average amount a HLS Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1733
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | HLTRF | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 0.76 actual daily | 6 94% of assets are more volatile |
Expected Return
| 0.13 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average HLS Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of HLS Therapeutics by adding it to a well-diversified portfolio.
HLS Therapeutics Fundamentals Growth
HLS Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of HLS Therapeutics, and HLS Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on HLS Pink Sheet performance.
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0276 | |||
| Profit Margin | (0.35) % | |||
| Operating Margin | (0.19) % | |||
| Current Valuation | 344.73 M | |||
| Shares Outstanding | 32.38 M | |||
| Price To Book | 1.86 X | |||
| Price To Sales | 4.41 X | |||
| Revenue | 60.01 M | |||
| EBITDA | 25.41 M | |||
| Cash And Equivalents | 21.16 M | |||
| Cash Per Share | 0.65 X | |||
| Total Debt | 84.13 M | |||
| Debt To Equity | 0.63 % | |||
| Book Value Per Share | 4.06 X | |||
| Cash Flow From Operations | 16.43 M | |||
| Earnings Per Share | (0.37) X | |||
| Total Asset | 275.9 M | |||
About HLS Therapeutics Performance
By analyzing HLS Therapeutics' fundamental ratios, stakeholders can gain valuable insights into HLS Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if HLS Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if HLS Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada. Hls Therapeutics operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 92 people.Things to note about HLS Therapeutics performance evaluation
Checking the ongoing alerts about HLS Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for HLS Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 60.01 M. Net Loss for the year was (13.12 M) with profit before overhead, payroll, taxes, and interest of 50.36 M. | |
| About 64.0% of the company shares are owned by institutional investors |
- Analyzing HLS Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether HLS Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining HLS Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating HLS Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of HLS Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of HLS Therapeutics' pink sheet. These opinions can provide insight into HLS Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for HLS Pink Sheet analysis
When running HLS Therapeutics' price analysis, check to measure HLS Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy HLS Therapeutics is operating at the current time. Most of HLS Therapeutics' value examination focuses on studying past and present price action to predict the probability of HLS Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move HLS Therapeutics' price. Additionally, you may evaluate how the addition of HLS Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |